Efficacy analysis of rituximab in treating patients with primary membranous nephropathy dependent on calcineurin inhibitors
RTX effectively achieves complete clinical and immunological remission in PMN patients dependent on or partially responsive to long-term CNI therapy, reducing recurrence and minimizing prolonged immunosuppressive therapy risks.
Authors
- Tingting Zhao (ORCID: https://orcid.org/0000-0002-5848-6061)
- Hong‐Gang Wang (ORCID: https://orcid.org/0000-0003-0551-0571)
- Bing Chen (ORCID: https://orcid.org/0000-0003-1038-0847)
- Zhuo Li (ORCID: https://orcid.org/0000-0001-7775-2831)
- Shasha Zhang (ORCID: https://orcid.org/0000-0003-3431-7615)
- Rong Wang (ORCID: https://orcid.org/0000-0003-1341-4731)
- Jing Huang (ORCID: https://orcid.org/0000-0002-1755-5008)
- Yujiao Sun
Institutions
- Shandong University (CN)
- Second Hospital of Shandong University (CN)
- Shandong Provincial Hospital (CN)
- Shanghai East Hospital (CN)
- Hanzhong People's Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.3389/fimmu.2024.1504646
- Citations
- 3
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 1.02